⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MIRM News
Mirum Pharmaceuticals, Inc. Common Stock
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
MIRM
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
businesswire.com
MIRM
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
businesswire.com
MIRM
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
businesswire.com
MIRM
Form 8-K
sec.gov
MIRM
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
businesswire.com
MIRM
Form 8-K
sec.gov
MIRM
Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
businesswire.com
MIRM
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
businesswire.com
MIRM
Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
businesswire.com
MIRM